A common, preventable, and treatable disease characterised by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities, typically resulting from extensive exposure to noxious particles or gases, and influenced by host factors including abnormal lung development is Chronic Obstructive Pulmonary Disease (COPD). The purpose of this research was to compare the previously established BAP65 score to the newly developed DECAF score for its ability to predict mortality and the requirement for IMV in patients admitted to the intensive care unit with AECOPD. Methods: Fifty people with COPD exacerbation were included in this research from our emergency rooms and intensive care units at Benha University. Comparison of BAP 65 score components between survivors and patients who passed away revealed statistically significant differences for BUN >25 (21.43 percent in the discharged group versus 62.50 percent in the died group, P = 0.018), Altered mental status (11.90 percent in the discharged group versus 50.00 percent in the died group, P = 0.026), and pulse >109 bpm (21.43 percent in the discharged group versus 75.00 percent in the died group, P = 0.002). Ages >65 did not significantly differ between the two groups (40.48 percent in the discharged group vs 75.00 percent in the dying group, P = 0.073). Conclusions: COPD is a severe health disease that affects patient health and life, and represents a burden for the health services. The mean value of BAP 65 score was 2.191.04 in the discharged group, and 3.751.58 in the deceased group, with a very significant difference between groups (P= 0.001). Early identification and adequate care of COPD improves patient prognosis since exacerbations are the leading cause of death in COPD patients. A patient's prognosis during AECOPD may be evaluated using not just clinical judgement, but also the BAP65 and DECAF scoring systems, which take into account a variety of parameters.